Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Novartis : LAND CONSERVANCY GETS HELPING HANDS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/29/2016 | 01:00pm CEST

As part of the Novartis Group's 20th annual Community Partnership Day, a group of employees spent a workday at The Land Conservancy of New Jersey in Boonton.

The Land Conservancy of New Jersey is a nonprofit, member supported land trust, dedicated to preserving and protecting open spaced lands and valuable water resources.

Novartis associates raked, planted, cleared debris and brush to beautify the organization's headquarters, WildAcres, a 44-acre public park.

Worldwide, more than 27,500 Novartis associates are dedicating an estimated 220,000 hours to volunteer with charitable causes in their communities to celebrate Community Partnership Day.

These Novartis Pharmaceuticals Corporation volunteers were among more than 5,000 associates in the U.S. who provided hands-on support that benefited more than 175 nonprofit agencies.

Community Partnership Day aims to provide opportunities for associates to give their time, expertise and ideas to volunteering efforts that foster a deeper connection with the patients we support and in the communities where we live.

"Community Partnership Day has been a traditional day of volunteer service at Novartis for 20 years, bringing together associates around the world and across functions to support our nonprofit partners and the important work that they do," said Amy Fry, vice president, communications and patient relations, Novartis Pharmaceuticals Corporation. "It's a fun and rewarding day to volunteer together and support our mission of discovering new ways to extend and improve people's lives."

© (c) 2016 The Neighbor News, North Jersey Media Group, Inc. All Rights Reserved., source Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
04/28 NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
04/28 NOVARTIS : receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acu..
04/28 NOVARTIS : to globally co-commercialise Amgens migraine drug
04/27 NOVARTIS : Patent Issued for Formulation Comprising Benzothiazolone Compound (US..
04/27 NOVARTIS : Allergan Expands Leading Research & Development NASH Program with Nov..
04/27 NOVARTIS : NIH study in NEJM shows Novartis drug eltrombopag as first-line thera..
04/27 NOVARTIS : Patent Issued for Process for Preparing Intermediates Useful in the M..
04/27 NOVARTIS : Patent Issued for Process for Manufacturing an Ophthalmic Lens (USPTO..
04/27 NOVARTIS : Patent Issued for Method for Making Contact Lenses (USPTO 9623614)
04/27 NOVARTIS : Patent Issued for Pharmaceutical Composition (USPTO 9622975)
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 FDA OKs Novartis' leukemia med Rydapt
04/27 BRISTOL-MYERS SQUIBB : Becoming An Increasingly Attractive Target
04/27 Amgen's Q1 Shows Challenges And Growth Opportunities Aplenty
04/27 G1 Therapeutics Seeks $115 Million IPO
04/27 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 28, 2017
Advertisement
Financials ($)
Sales 2017 48 401 M
EBIT 2017 12 341 M
Net income 2017 7 465 M
Debt 2017 14 141 M
Yield 2017 3,65%
P/E ratio 2017 22,62
P/E ratio 2018 19,91
EV / Sales 2017 4,50x
EV / Sales 2018 4,30x
Capitalization 203 449 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 79,7 $
Spread / Average Target 3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.77%203 449
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
SANOFI11.79%120 647
More Results